Development and validation of a driving simulator for evaluating the residual effects of drugs on driving performance – sensitivity analysis using zopiclone as a positive control

Study Protocol Clinical Trial (SPIRIT Compliant)

Mari Iwata, MD³, Kunihiro Iwamoto, MD, PhD⁴,*, Daiji Kambe, PhD⁵, Naoki Tachibana, MS⁵, Masahiko Ando, MD, PhD⁶, Norio Ozaki, MD, PhD⁷

Abstract

Introduction: Drugs acting on the central nervous system (CNS), especially hypnotics, can impair driving. The US Food and Drug Administration started requiring pharmaceutical companies to evaluate the residual influence of CNS agents on driving performance to review their recommended doses. Although it is important for physicians to discuss automobile driving while on medication with patients to promote traffic safety, the package inserts of most CNS agents in Japan uniformly prohibit patients from driving. Although more evidence-based information regarding the effects of drugs on driving performance is needed, the current evaluation methods for driving performance abroad cannot be applied directly to Japanese drivers because of differences in traffic environments, laws, and constitutions. Therefore, we plan to establish a new driving simulator (DS) that would enable the next-day residual effects of drugs on driving performance to be examined.

Methods: In this double-blind, randomized, placebo-controlled, crossover trial, we plan to recruit 26 healthy Japanese males aged 21 to 64 years through advertisements. During the test periods, which will take place twice every other week, the participants will undergo a DS evaluation in the hospital for 2 days/1 night after the first and last doses of the study drug following 8 days of administration. The participants in the study drug group will take zopiclone 7.5 mg at bedtime on the first and eighth days in the hospital, and placebo on the other days. The DS evaluation consists of road tracking, car following, and harsh braking tests. The primary outcome is the standard deviation of lateral position (SDLP), which is a gold standard evaluation item, in the 60-min road-tracking test. The exploratory outcomes are other evaluation items in the DS tests, in the Karolinska Sleepiness Scale sleep questionnaire, and the Profile of Mood States Second Edition rating scale. The estimated difference in the SDLP between the zopiclone and placebo groups will then be calculated.

Trial registration: This study was registered at ClinicalTrials.gov NCT 04108351, on September 30, 2019. Ethics approval was obtained from the Ethics Committee at Hakata Clinic and the Nagoya University Medical School Hospital Bioethics Review Committee.

* MI and KI contributed equally to this paper.

This trial is supported by Taisho Pharmaceutical Company, Ltd.; Research on Regulatory Science of Pharmaceuticals and Medical Devices from the Japan Agency for Medical Research and Development (JP19mk010113kh0001); research grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan; the Ministry of Health, Labour and Welfare of Japan; a Grant-in-Aid from the “Center of Innovation for Personalized and Diverse Society” carried out under the Center of Innovation Program from the Japan Science and Technology Agency.

MI has no conflicts of interest to declare. KI has received speakers’ honoraria from, or has served as a consultant to, Dainippon Sumitomo, Janssen, Meiji Seka Pharma, Mochida, Otsuka, Taisho, Takeda, Tanabe Mitsubishi, and Pfizer. DK and NT are employees of Taisho Pharmaceutical Co., Ltd., Japan. MA has received subsidies from Eisai. NO has received research support or speakers’ honoraria from, or has served as a consultant to, Abbvie, Asahi Kasei Pharma, Astellas, Dainippon Sumitomo, Eisai, Eli Lilly, GlaxoSmithKline, Janssen, Meiji Seka Pharma, Mochida, MSD, Novartis Pharma, Otsuka, Pfizer, Shionogi, Takeda, Tanabe Mitsubishi, Sanofi, and Yishimoto.

³ Department of Psychiatry, Nagoya University, Graduate School of Medicine, Nagoya, Aichi; ⁴ Development Planning, Taisho Pharmaceutical Co., Ltd., Tokyo; ⁵ Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Aichi, Japan.

* Correspondence: Kunihiro Iwamoto, Department of Psychiatry, Nagoya University, Graduate School of Medicine, 65 Tsurumai, Showa, Nagoya, Aichi 466-8550, Japan (e-mail: iwamoto@med.nagoya-u.ac.jp).

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Iwata M, Iwamoto K, Kambe D, Tachibana N, Ando M, Ozaki N. Development and validation of a driving simulator for evaluating the residual effects of drugs on driving performance – sensitivity analysis using zopiclone as a positive control. Study Protocol Clinical Trial (SPIRIT Compliant). Medicine 2020;99:12 (e19395).

Received: 31 January 2020 / Accepted: 3 February 2020
http://dx.doi.org/10.1097/MD.00000000000019395
1. Introduction

Drugs acting on the central nervous system (CNS) have side effects such as drowsiness, dizziness, light-headedness, and reduced attention, which can impair driving. In regard to CNS agents, epidemiological studies have reported a relationship between traffic accidents and the use of hypnotics, anxiolytics, and antidepressants. These findings raise serious concerns about the balance between individual rights and public safety when driving under the influence of CNS agents. The World Health Organization has pointed out that the influences of drugs on driving are not negligible, and published a policy regarding drug use and road safety. In particular, the effects of hypnotics on automobile driving are attracting increasing attention. The next-day blood concentration of zolpidem, one of the most frequently prescribed hypnotics, may be high enough to impair activities that require attention, such as driving. Therefore, the US Food and Drug Administration (FDA) reduced the recommended dose for zolpidem, issued a warning in regard to driving the day after hypnotics use, and reviewed the recommended dose for all hypnotics. As a result, the FDA now requires pharmaceutical companies to evaluate the influences of CNS agents on driving. In regard to the residual effects of hypnotics on driving performance, recently developing hypnotics with antagonistic actions on orexin receptors, suvorexant, has been determined its recommended dose. In addition, a CNS agent other than hypnotics, ibanserin was required to study its effects on driving performance and has been approved.

In European Union nations, highway driving tests have long been established as an evaluation system for the effects of drugs on driving performance, and all drugs are classified into four categories according to degree of risk based on epidemiological and experimental studies and the occurrence of adverse events. Sharing such information in discussions with patients and medical staff is considered important for traffic safety. Evidence-based information regarding drugs and driving is provided in this manner in Europe and the US. However, in Japan, almost all CNS agent package inserts, except those for some antidepressants, uniformly prohibit patients from driving while on medication regardless of the patient’s condition and drug-treatment period, and harsher penalties for being involved in traffic accidents while on medication have also been enacted. Due to such uniform regulations, there are few opportunities for medical staff to discuss automobile driving while on medication with patients; thus, the daily lives of many patients in Japan are restricted.

One of the reasons for this lack of opportunities is that no standardized evaluation method for driving performance has been established in Japan. Although many researchers use their own methods for assessing driving performance, no existing method in Japan has been confirmed in terms of validity or reliability. The evaluation system considered the gold standard uses actual vehicles on the highway in the Netherlands. The standard deviation of lateral position (SDLP), which indicates vehicular weaving, has been confirmed in terms of test–retest reliability and validity for alcohol. The validity of this index has also been confirmed for acute, chronic, and next-day residual effects on driving performance after administration of positive control drugs. However, this system is only applied on Dutch highways. In addition, the traffic environment in the Netherlands differs from that in Japan; thus, safety and economic issues remain.

A driving simulator (DS) could be expected to resolve these issues. Although a DS evaluation system for the acute effects of alcohol and the residual effects of zopiclone has already been used for new drug applications in the US, this system cannot be applied in Japan because of differences in the traffic environments. In addition, few evaluation systems can assess the next-day residual effects of drugs on driving performance. In other words, the establishment of a DS evaluation system in Japan would enable the effects of drugs on driving performance to be investigated, provide useful information for patients and doctors in the future, and contribute to traffic safety.

With this background, we developed a new DS evaluation system for alcohol and carried out validation, the results of which are currently being analyzed. To confirm the validity of the system, a trial comparing a positive control drug with placebo is required as the next step. Therefore, we planned to establish a new DS evaluation system that assesses the residual effects of hypnotics on driving performance for Japanese. The primary endpoint is the SDLP, the validity of which has been repeatedly confirmed. To verify the residual effects of hypnotics, which has become an increasingly popular topic in recent years, this protocol will verify the analytical sensitivity of the evaluation system using zopiclone, which has been used repeatedly as a positive control in actual driving tests. Zopiclone is a commonly used benzodiazepine receptor agonist with well-known residual effects on driving performance, and has been proposed as a positive control for studying the safety of hypnotics. Zopiclone has been used in previous studies involving DS research to verify the CRCDS Mini-Sim, and as a positive control in actual driving tests to examine the effects of lemborexant, suvorexant, and ramelteon on driving performance. This study was designed to examine, using the new DS, the next-day effects of zopiclone 7.5 mg (taken at bedtime) on driving performance.

2. Methods

2.1. Study design

This study is planned as a double-blind, randomized, placebo-controlled, crossover trial. Taisho Pharmaceutical Co., Ltd., will be conducting the clinical trial at Fukuoka Mirai Hospital in Japan. The purpose of this study is to evaluate driving
performance by repeated administration of hypnotics (zopiclone 7.5 mg), and to confirm that zopiclone has analytical sensitivity as a positive control in the new DS evaluation system. The administration period is 8 days each in test periods 1 and 2. A practice period with the same contents as the test periods will be carried out to allow the participants to become accustomed to operating the DS. Each driving performance evaluation will be conducted during a 2-day/1-night hospital stay, with a 7-day interval between tests.

### 2.2. Participants

Healthy Japanese male volunteers will be recruited through advertisements online and at Fukuoka Mirai Hospital. The sample size was set at 26 with reference to previous studies examining the analytical sensitivity of a DS test system. The inclusion criteria are as follows: age range 21 to 64 (inclusive) years; body mass index 18.5 to 25.0 kg/m²; possession of a driver’s license and driving on a daily basis for ≥3 years; consistent sleeping pattern (awaken between 06:00 AM and 09:00, go to bed between 09:00 PM and 00:00); no visual impairments; able to operate a DS with a full understanding of all DS tasks; judged by a physician as being able to participate; and able to provide written informed consent before the examination begins. The exclusion criteria are: having a disease recognized as being non-healthy by a physician; a history of drug or food allergies; serious allergic predispositions; a history of hypersensitivity to zopiclone; a history of stroke, head trauma, epilepsy, or malignant tumor; a 3-month or longer history of sleep disorders, a medical history of sleep apnea syndrome or restless legs syndrome, or a history of hypersomnia or narcolepsy; use of any medication, including over-the-counter drugs, within 1 week before starting the practice period; use of sedative hypnotics within 4 weeks before starting the practice period; experiencing a 6-hour or longer time difference from 4 weeks before starting the practice period until test completion; irregular shift work and night shift work within 4 weeks before starting the practice period; and judged unsuitable for participation by a physician.

### 2.3. Randomization and blinding

Participants will be randomly assigned to the zopiclone and placebo groups at a ratio of 1:1 (Table 1). Randomization will be conducted based on a computer-generated random number table. The allocation table conducted by an assignment manager will not be disclosed until all data are fixed. Since the zopiclone tablets might be visibly distinguishable from the placebo tablets, they will be placed in an opaque container and administered in a manner to ensure blinding on the test day. The assignment manager and institution for measuring serum zopiclone concentrations will be disclosed to the investigators.

### 2.4. Study drug

Participants will be administered zopiclone 7.5 mg tablets as the active drug and placebo as the control drug. The study drug will be orally administered with 150 mL of water at bedtime on the day before the DS test. The single dose of zopiclone was set to 7.5 mg, which is used in daily medical care, with reference to existing driving tests and package inserts. Since the tablet shape differs between the active and placebo drugs, it will be necessary to control for participant prejudice (e.g., sight, touch). Therefore, blinding will be maintained by administering both zopiclone and placebo tablets in the zopiclone group and two placebo tablets in the placebo group. For 6 days from the DS evaluation date during the test period, the zopiclone and placebo groups will both be instructed to take two placebo tablets at home. The administration period will be 8 days each in test periods 1 and 2 (16 days in total). To measure blood exposure, all participants will undergo blood sampling after the DS evaluation.

### 2.5. Test schedule

The test schedule is shown in Table 2. The test is divided into a screening period, a practice period, and two test periods, with 7-day intervals between each period. In each test period, two inspections for 2 days/1 night will be performed on the next day of first and last administration. All participants will be assessed in terms of background characteristics and undergo medical and ophthalmic examinations, a vital sign check, electrocardiogram, blood test, and urinalysis during the screening period. Medical examinations will be performed and vital signs checked at each hospital stay before the DS task and at discharge. The study drug will be administered with 150 mL of water at bedtime on the

### Table 1

| Periods           | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | Day 8 |
|-------------------|-------|-------|-------|-------|-------|-------|-------|-------|
| Placebo period    | P+P   | P+P   | P+P   | P+P   | P+P   | P+P   | P+P   | P+P   |
| Zopiclone period | Z+P   | P+P   | P+P   | P+P   | P+P   | P+P   | P+P   | Z+P   |
| Place of administration | Hospital | Hospital |

P = Placebo, Z = Zopiclone.
Table 2
Test schedule.

| Test schedule | Test period 1 | Test period 2 | Test period 3, 4 |
|---------------|---------------|---------------|------------------|
| Day -1 | Day 1 | Day 2, 25 | Day 3, 24 |
| Screening admission | after appropriate judgement | after DS evaluation | before discharge |
| Discharge | admission | before DS evaluation | after DS evaluation |
| After DS evaluation | Discharge | before DS evaluation | after DS evaluation |
| Discharge | Home admission | before DS evaluation | Discharge |
| Discharge | Evaluation/evaluation | Discharge | Discharge |
| Discharge | Discharge | Discharge | Discharge |

Iwata et al. Medicine (2020) 99:12

Table 3
Time schedule of the test period.

| Time from discharge | Day 1 |
|---------------------|------|
| Admission (evening) | Medical examination and vital sign check |
| DS test driving | Dinner |
| Going to bed | |
| Day 2 | |
| Waking up and breakfast | Sleep questionnaire |
| Medical examination and vital sign check | |
| 8.5 hours | KSS / POMS 2 |
| 10 hours | Road-tracking test |
| 10.5 hours | Car-following test |

Table 2 includes various test procedures and their scheduling during different periods of the study. Table 3 provides a detailed schedule of activities from admission to discharge. The text explains the purpose and methodology of these tests, focusing on the use of a driving simulator and the measurement of various outcomes to evaluate driving performance.

2.6. DS evaluation

The DS evaluation consists of three tasks. In the first task, a road-tracking test, participants are instructed to drive in the center of the lane while maintaining a speed of 100 km/h on a two-lane road with a gentle curve. The SDLP is the primary measurement. The measurement time is 60 minutes from 9 hours after taking the study drug. The next task is a car-following test, where participants are instructed to maintain a constant intervehicle distance from a preceding vehicle with varying speeds. This test measures the distance coefficient of variation (DCV), which is obtained by dividing the standard deviation of the distance between vehicles by the average. The measurement time is 5 minutes from 10 hours after taking the study drug. In the last task, a harsh braking test, participants are instructed to maintain a constant speed of 50 km/h and avoid colliding with humanoid models randomly appearing from either side of the road by harsh braking. This test takes about 5 minutes and is conducted continuously after the completion of the car-following task.

2.7. Primary outcome

The primary endpoint is the SDLP, which represents the distance from the center line of the road to the right edge of the vehicle body in the road tracking task. This is the most sensitive indicator and the only one validated and reliable, to evaluate driving ability after the administration of CNS drugs. Since the SDLP has been used as a primary outcome in previous reports to evaluate the effects of drugs on driving performance, it was also set as the primary outcome in the present DS study.

2.8. Exploratory outcomes

The following outcomes will be used as exploratory evaluation items: total number of times the car body crosses; the lane (inappropriate line crossing; ILC); total number of times the vehicle goes off of the course (total course-outs; TCO); standard deviation of speed in the road tracking test; the DCV to the preceding vehicle in the car following test; reaction time for detecting deceleration of...
the preceding vehicle (time to speed adaptation); number of collisions with the preceding vehicle (car collisions) in the car following test; brake reaction time (BRT); and number of collisions with an object (error) in the harsh braking test.

2.9. Other outcomes

In addition to the DS evaluation items, an exploratory analysis of the following will also be conducted. The Japanese versions of POMS 2 and the KSS[28] will be performed in consideration of the possibility that drowsiness and mood at the time of the examination could affect the results. The participants will also self-evaluate their sleep (e.g., sleep latency, number of awakenings, wake time after sleep onset, total sleep time) subjectively using questionnaires at the time of awakening.

2.10. Statistical analysis

Primarily, basic statistics for 60-minute cumulative SDLP will be calculated, as will basic statistics for the difference (∆SDLP) between the positive control drug (zopiclone) and placebo groups and the two-sided 90% confidence interval (CI) of the mean difference. If both lower limits of the two-sided 90% CIs of ∆SDLP at each inspection are greater than 0cm, zopiclone will be judged to have analytical sensitivity. Secondarily, the frequency of ∆SDLP categories will counted and a symmetry analysis will be conducted.

2.11. Adverse events

If any adverse events occur after the start of the practice period, the study can be discontinued based on the doctor’s or participant’s own decision in accordance with severity. Adequate medical care will be provided to the participants in the case of any adverse event. All adverse event data will be monitored and reported in detail at a later date, but will not be aggregated or analyzed.

2.12. Ethics and dissemination

This study was registered at ClinicalTrials.gov (NCT 04108351) on September 30, 2019. The study protocol was approved by the Ethics Committee at Hakata Clinic (1747CP-4) and the Nagoya University Medical School Hospital Bioethics Review Committee (2010-970-4). The study will be carried out at Fukuoka Mirai Hospital. Informed consent will be obtained from all study participants. For privacy protection, all participants will be identified using an anonymous identification code. Information such as the participant’s name and address will be managed by only the medical examination center, and will not be provided to other organizations. If any necessary experimental data are provided to a joint research institution (investigator and sponsor), these will be carefully protected using only the participants’ identification codes and a corresponding table. The sponsor and investigator will have access to the final test data. The acquisition of informed consent, the inclusion/exclusion criteria, participant eligibility, and the occurrence of any adverse events will be confirmed by monitors from outside the testing agency. These monitors will ascertain whether the experiment is being carried out according to the approved procedure and confirm that the data storage method is appropriate. We will also set up an independent auditor from the testing department to evaluate whether the experiment complies with the protocol. All test-related data will be disclosed to the monitor or auditor for the purposes of conducting a survey. To publicize and explain the research to key audiences, the experimental results will be aimed at publication in a peer-reviewed journal and presented at local, national, and international conferences.

3. Discussion

The objective of the proposed study is to verify the analytical sensitivity of a DS evaluation system using zopiclone in healthy Japanese volunteers. Any DS system close to the actual vehicle test in the Netherlands, which is the gold standard for evaluating the effects of drugs on driving performance, must satisfy several conditions, including

1) validation of the acute effects of alcohol drinking,
2) validation of the residual effects of positive control drug administration, and
3) verification of test–retest reliability.

However, no existing DS evaluation system currently satisfies all of these conditions. Although validation with alcohol and positive control drugs are examined in the CRCDS Mini-Sim[23] and DS of Green Dino,[29] it is difficult to apply these DSSs to verification in Japan because of differences in driving environments.

Zopiclone is a widely used hypnotic, and its effect on the driving performance has been repeatedly reported.[19,20,31,32] In fact, an epidemiological study showed that zopiclone users are four times more likely to be involved in traffic accidents.[12] Therefore, in driving studies, zopiclone has been used most frequently as a positive control to validate residual effects.[13,15] In addition, amitriptyline,[13,15] mirtazapine,[16,36,37] and recently, alprazolam,[29] may be used as positive control drugs. We selected zopiclone as the positive control drug in this study because it has been used for not only actual vehicle tests, but also other DS validations.[23] Females are generally more likely than males to be affected by drugs,[18] however, no significant sex or age differences in the effects of zopiclone on driving performance have been reported.[19]

The SDLP, as the primary end point, has a threshold equivalent to a blood alcohol concentration (BAC) of 0.05%, which is the legal limit in many countries, and is known to increase in parallel with BAC.[12] In general, the SDLP often shows a larger value in DS systems than in actual vehicle tests. On the other hand, zopiclone 7.5mg has been reported to increase the SDLP and to have an effect equivalent to a BAC of 0.05 to 0.08%.[39] Most previous studies have found that zopiclone significantly increases the SDLP the day after administration, although the measurement time after administration has varied with respect to each experiment.[19,20,31,32] The SDLP measured in the acute phase (5–6 hours after administration) has been reported to be increased,[41] whereas that at 16 hours after administration has not.[20,31,42] Given this background, and in reference to the previous reports,[20,22,26] the present study will be conducted 9 to 10 hours after administration, at which time driving performance is expected to be affected. In general, hypnotics are known to increase the risk of traffic accidents with increases in drug half-life and to decrease after repeated administration.[42,43] Zopiclone is an ultra-short-acting hypnotic with a maximum blood concentration time (Tmax) of about 1 hour and a blood elimination half-life (T1/2) of about 4 hours. However, since the residual effect of zopiclone on driving performance has been repeatedly reported even at about 9 hours after administration, when the blood
elimination half-life is exceeded, it seems to be an appropriate established time for the next day after administration. Other secondary evaluation items vary based on previous reports, and the results are not necessarily consistent. For example, many studies have reported significant effects of zopiclone on the standard deviation of speed (SDS),[10,19,21,33,39] whereas others have not.[23,25,30] In this study, we included SDS as an exploratory item. Since lane exceedance and road exits, which indicate that the SDLP exceeds a certain level, have had significant effects in some investigations,[21,23] this study may reveal increases in ILC and TCO. One prior report found that zopiclone significantly increased the number of collisions in the car following test.[11] As the DCV is considered to predict the number of collisions, it is therefore likely to be a predictor of accident risk; thus, measuring DCV is considered to be highly meaningful. Although BRT is said to be sensitive to the effects of psychotropic drugs on driving,[44] eszopiclone, an optical isomer of zopiclone, had no effect on next-day BRT in both healthy and patient groups.[45] However, most of these studies have involved healthy participants, and thus, further studies on different patient populations will be required in the future.

DS systems, although comprehensive, cannot reproduce actual traffic situations fully. For this reason, there are limitations in using a DS system to evaluate all types of driving performance necessary for actual traffic conditions. However, even actual vehicle tests regarded as a gold standard cannot evaluate all types of driving performance. Therefore, to promote road safety, it is important to accumulate evidence, including secondary evaluation items, and provide opportunities for patients and medical staff to discuss automobile driving while on medication.

If the residual effects of zopiclone as a positive control drug could be confirmed, the results as evaluated by the present DS system would be considered scientifically valid, which would make it possible to evaluate the effects of drugs on driving performance accurately in Japanese people, thereby providing useful information to both doctors and patients.

Acknowledgments

The authors would like to thank the following employees at the Department of Clinical Development and Development Planning at Taisho Pharmaceutical Co., Ltd., who made valuable contributions to the development of the study protocol: Yumiko Imadera, Hiroshi Sunaga, Kazuma Nishiwaki, Chiaki Naruse, Yuusuke Miyazaki, Sayaka Hasegawa, and Hiroki Ogo.

Author contributions

NO developed the study concept with MI, IK, DK and NT; MI and IK wrote the first draft of the manuscript, and DK, NT, MA and NO made critical revisions to the manuscript; all authors read and approved the final manuscript to be submitted.

References

[1] Chang CM, Wu EC, Chen CY, et al. Psychotropic drugs and risk of motor vehicle accidents: a population-based case-control study. Br J Clin Pharmacol 2013;75:1123–33.
[2] Orruols L, Philip P, Moore N, et al. Benzodiazepine-like hypnotics and the associated risk of road traffic accidents. Clin Pharmacol Ther 2011;89:595–601.
[3] Ravera S, van Rein N, de Gier JJ, et al. Road traffic accidents and psychotropic medication use in The Netherlands: a case-control study. Br J Clin Pharmacol 2011;72:505–13.
[4] Orruols L, Quenec R, Philip P, et al. Risk of injurious road traffic crashes after prescription of antidepressants. J Clin Psychiatry 2012;73:1088–94.
[5] World Health Organization. Drug use and road safety: a policy brief. 2016. http://apps.who.int/iris/bitstream/handle/10665/249533/WHO-MSD-NVI-2016.01-eng.pdf?sequence=1. [access date October 22, 2019].
[6] Kuehn BM. FDA warning: Driving may be impaired the morning following pill use. JAMA 2013;309:645–6.
[7] Farkas RH, Unger EF, Temple R, Zolpidem and driving impairment–identifying persons at risk. N Engl J Med 2013;369:689–91.
[8] US Food and Drug Administration. FDA drug safety communication: risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist). 2013; https://www.fda.gov/downloads/drugs/drugsafety/ucm355007.pdf. [access date on October 22, 2019].
[9] US Food and Drug Administration. Evaluating Drug Effects on the Ability to Operate a Motor Vehicle Guidance for Industry. 2017; https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM430374.pdf. [access date on October 22, 2019].
[10] Vermeeran A, Sun H, Vuurman EF, et al. On-the-road driving performance the morning after bedtime use of suvorexant 20 and 40 mg: a study in non-elderly healthy volunteers. Sleep 2015;38:1803–13.
[11] Kay GG, Hochadel T, Scard E, et al. Next-day residual effects of filharznerin on simulated driving performance in premenopausal women. Hum Psychopharmacol 2017;32:e2603.
[12] Verster JC, Rooth T. Standard operation procedures for conducting the on-the-road driving test, and measurement of the standard deviation of lateral position (SDLP). Int J Gen Med 2011;4:359–71.
[13] Iwata M, Iwamoto K, Kawano N, et al. Evaluation method regarding the effect of psychotropic drugs on driving performance: A literature review. Psychiatry Clin Neurosci 2018;72:747–73.
[14] Ravera S, Monteiro SP, de Gier JJ, et al. A European approach to categorizing medicines for fitness to drive: outcomes of the DRUID project. Br J Clin Pharmacol 2012;74:520–31.
[15] Verster JC, Spence DW, Shahid A, et al. Zopiclone as positive control in studies examining the residual effects of hypnotic drugs on driving ability. Curr Drug Saf 2011;6:209–18.
[16] Verster JC, van de Loo AJ, Roth T. Mirtazapine as positive control drug in studies examining the effects of antidepressants on driving ability. Eur J Pharmacol 2015;753:252–6.
[17] Iwata M, Iwamoto K, Omura T, et al. Protocol for the development and validation of a driving simulator for evaluating the influence of drugs on driving performance. Medicine (Baltimore) 2019;98:e14613.
[18] Walsh JM, Verstraete AG, Huets MA, et al. Guidelines for research on drug驾驶. Addiction 2008;103:1258–68.
[19] Leukens TR, Ramaekers JG, de Weerd AW, et al. Residual effects of zolpidem 7.5 mg on highway driving performance in insomnia patients and healthy controls: a placebo controlled crossover study. Psychopharmacology (Berl) 2014;231:2785–98.
[20] Bocca ML, Le Doze F, Etard O, et al. Residual effect of zolpidem 10 mg and zopiclone 7.5 mg versus flunitrazepam 1 mg and placebo on driving performance and ocular saccades. Psychopharmacology (Berl) 1999;143:373–9.
[21] Bocca ML, Marie S, Lelong-Boulouard V, et al. Zopiclone and zolpidem impair similarly monotonous driving performance after a single nighttime intake in aged subjects. Psychopharmacology (Berl) 2011;214:699–706.
[22] Vermeeran A, Riedel WJ, van Boxtel MP, et al. Differential residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol. Sleep 2002;25:224–31.
[23] Sunen AA, Gargano C, Cha JH, et al. A randomized, crossover, placebo-controlled clinical trial to assess the sensitivity of the CRCDS Mini-Sim to the next-day residual effects of zopiclone. Ther Adv Drug Saf 2015;6:86–97.
[24] Vermeeran A, Jongen S, Murphy P, et al. On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers. Sleep 2019;42:22460 doi:10.1093/deep/zsy260.
[25] Mets MA, de Vries JM, de Senerpont Domis LM, et al. Next-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjects. Sleep 2011;34:1327–34.
[26] Harrison C, Subhan Z, Hindmarsh I. Residual effects of zopiclone and benzodiazepine hypnotics on psychomotor performance related to car driving. Drugs Exp Clin Res 1985;11:823–9.
[27] Verster JC, Roth T. Effects of central nervous system drugs on driving: speed variability versus standard deviation of lateral position as outcome measure of the on-the-road driving test. Hum Psychopharmacol 2014;29:19–24.

[28] Kaida K, Takahashi M, Akerstedt T, et al. Validation of the Karolinska sleepiness scale against performance and EEG variables. Clin Neurophysiol 2006;117:1574–81.

[29] Huizinga CR, Zuiker RG, de Kam ML, et al. Evaluation of simulated driving in comparison to laboratory-based tests to assess the pharmacodynamics of alprazolam and alcohol. J Psychopharmacol 2019;33:791–800.

[30] Leufkens TR, Vermeeren A. Highway driving in the elderly the morning after bedtime use of hypnotics: a comparison between temazepam 20 mg, zopiclone 7.5 mg, and placebo. J Clin Psychopharmacol 2009;29:432–8.

[31] Leufkens TR, Lund JS, Vermeeren A. Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem. J Sleep Res 2009;18:387–96.

[32] Barbone F, Mc Mahon AD, Davey PG, et al. Association of road-traffic accidents with benzodiazepine use. Lancet 1998;352:1331–6.

[33] Iwamoto K, Takahashi M, Nakamura Y, et al. The effects of acute treatment with paroxetine, amitriptyline, and placebo on driving performance and cognitive function in healthy Japanese subjects: a double-blind crossover trial. Hum Psychopharmacol 2008;23:399–407.

[34] O’Hanlon JF. Driving performance under the influence of drugs: rationale for, and application of, a new test. Br J Clin Pharmacol 1984;18 Suppl 1:121S–9S.

[35] Robbe HW, O’Hanlon JF. Acute and subchronic effects of paroxetine 20 and 40 mg on actual driving, psychomotor performance and subjective assessments in healthy volunteers. Eur Neuropsychopharmacol 1995;5:335–42.

[36] Wingen M, Bothmer J, Langer S, et al. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry 2005;66:436–43.

[37] Sasada K, Iwamoto K, Kawano N, et al. Effects of repeated dosing with mirtazapine, trazodone, or placebo on driving performance and cognitive function in healthy volunteers. Hum Psychopharmacol 2013;28:281–6.

[38] Anderson GD. Gender differences in pharmacological response. Int Rev Neurobiol 2008;83:1–0.

[39] Leufkens TR, Vermeeren A. Zopiclone’s residual effects on actual driving performance in a standardized test: a pooled analysis of age and sex effects in 4 placebo-controlled studies. Clin Ther 2014;36:141–50.

[40] Ramaekers JG, Conen S, de Kam PJ, et al. Residual effects of esmirtazapine on actual driving performance: overall findings and an exploratory analysis into the role of CYP2D6 phenotype. Psychopharmacology (Berl) 2011;215:321–32.

[41] Vermeeren A, Danjou PE, O’Hanlon JF. Residual effects of evening and middle-of-the-night administration of zaleplon 10 and 20 mg on memory and actual driving performance. Hum Psychopharmacol 1998;13:598–107.

[42] Vermeeren A. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs 2004;18:297–328.

[43] Volkerts ER, Louwerens JW, Gloor ABM, et al. Zopiclone’s residual effect upon actual driving performance versus those of nitrazepam and flunitrazepam. Technical report VK-84-10 Groningen, The Netherlands; Traffic Research Center, University of Groningen; 1984.

[44] Hindmarch I, Subhan Z, Stoker MJ. The effects of zimeldine and amitriptyline on car driving and psychomotor performance. Acta Psychiatr Scand Suppl 1983;308:141–6.

[45] Boyle J, Trick L, Johnson S, et al. Next-day cognition, psychomotor function, and driving-related skills following nighttime administration of eszopiclone. Hum Psychopharmacol 2008;23:385–97.